Quote | Larimar Therapeutics Inc. (NASDAQ:LRMR)
Last: | $7.12 |
---|---|
Change Percent: | -1.27% |
Open: | $7.96 |
Close: | $7.12 |
High: | $7.96 |
Low: | $7.08 |
Volume: | 362,529 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
News | Larimar Therapeutics Inc. (NASDAQ:LRMR)
2024-05-09 17:05:29 ET More on Larimar Therapeutics Larimar Therapeutics rises after pricing $150M stock offering Larimar Therapeutics announces proposed underwritten public offering Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earni...
2024-05-09 07:56:23 ET More on Larimar Therapeutics Larimar Therapeutics rises after pricing $150M stock offering Larimar Therapeutics announces proposed underwritten public offering Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earni...
Message Board Posts | Larimar Therapeutics Inc. (NASDAQ:LRMR)
Subject | By | Source | When |
---|---|---|---|
could probably get through approval on just 25 | magacrew2020 | investorshub | 02/28/2023 11:21:47 PM |
znewcar1: LRMR 24% v2,7M c2.89 f17,7M H3.58 ML1.53 | znewcar1 | investorshangout | 08/19/2022 12:18:48 AM |
The company said it received feedback from the | subslover | investorshub | 08/12/2022 12:58:00 PM |
I voted NO on the 2022 Annual Meeting | JJJ54 | investorshub | 04/21/2022 1:11:30 AM |
Interesting. | DarkPool | investorshub | 02/14/2022 10:08:23 PM |
News, Short Squeeze, Breakout and More Instantly...
Larimar Therapeutics Inc. Company Name:
LRMR Stock Symbol:
NASDAQ Market:
First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was generally well-tolerated with dose-dependent increases in tissue frataxin le...
2024-04-26 19:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-16 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...